Paul Richardson, M.D.
As Clinical Director of the Myeloma Center beginning in January 2001, Dr. Richardson leads novel, biologically-derived translational efforts in multiple myeloma under the overall direction and mentorship of Kenneth Anderson, M.D.
Currently, he leads efforts studying the use of combination therapies predominantly in relapsed and refractory myeloma, his primary area of interest. He serves as a principal investigator and study chairman for several clinical trials relating to other areas of myeloma treatment, including the use of combination therapies in earlier disease designed to target resistance and reduce toxicity. His major leadership efforts are focused on the IFM/DFCI upfront study in patients eligible for stem cell transplant in combination with RVD. Finally, an important new area of interest for me is treatment-emergent neuropathy in myeloma, its characterization and strategies to minimize it.
Donald W. Kufe, M.D.
Dr. Kufe is a Professor of Medicine, Dana-Farber Cancer Institute and Harvard Medical School Department. Dr. Kufe received his M.D. from the University of Rochester School of Medicine. After a clinical fellowship in medical oncology at Dana-Farber Cancer Institute, he joined the staff in 1979. He has served as chief of the Division of Cancer Pharmacology, deputy director of the Dana-Farber/Harvard Cancer Center, director of the Harvard Phase I Oncology Group and leader of the Experimental Therapeutics Program.
He is an editor of the textbook "Cancer Medicine." Dr. Kufe is the recipient of the Richard P. and Claire W. Morse Scientific Award, DFCI, the Scholar Award, Burroughs-Wellcome and the Faculty Research Award, American Cancer Society. Dr. Kufe currently sits on the board of directors of Genus Oncology, LLC and Linus Pharmaceuticals, Inc., and from December 2003 to July 2009, he served as a director of Adherex Technologies Inc., a publicly traded biopharmaceutical company.
Surender Kharbanda, Ph.D.
Dr. Kharbanda received his Ph.D. in cell biology in 1986 from the All India Institute of Medical Sciences [AIIMS], New Delhi. He joined the Dana-Farber Cancer Institute, Harvard Medical School in 1986 as a Research Fellow and undertook extensive research work in the area of oncology drug discovery and development. In 1991, he was promoted to Assistant Professor at Harvard Medical School where he worked as a faculty member for 15 years.
Dr. Kharbanda is a co-author on more than 180 papers published in peer-reviewed scientific journals and holds > 20 patents and patent applications in the area of oncology drug discovery. In 2000, he joined Ilex Oncology Inc., an oncology-driven pharmaceutical company, as Vice-President [head of R&D], where his responsibilities included development of novel drugs for cancer. Dr. Kharbanda was a member of the team which successfully advanced three oncology drug candidates to human clinical trials. Following the acquisition of Ilex Oncology by Genzyme Corporation, Dr. Kharbanda founded companies that include Genus Oncology, Linus Oncology and NanoProteagen. Dr. Kharbanda is currently working at Genus as the Chief Scientific Officer and his focused goal is to develop novel therapeutic approaches for the treatment of diverse types of carcinomas.